摘要
目的比较英夫利西单抗(infliximab,IFX)及维得利珠单抗(vedolizumab,VDZ)在中重度溃疡性结肠炎(ulcerative Colitis,UC)治疗中的疗效及安全性差异。方法回顾性收集自2020年01月至2023年12月于昆明医科大学第一附属医院确诊为中重度UC并使用IFX/VDZ治疗的患者110例,其中IFX治疗组55例,VDZ治疗组55例。记录患者在治疗前(0周)及治疗14周、30周、54周的临床症状、疾病活动相关指标、内镜表现以及治疗过程中发生的不良反应,分析2种药物对于中重度UC治疗的疗效及安全性是否存在差异。结果2组患者在各项基线指标之间无显著差异(P>0.05);IFX治疗组的炎症指标(WBC、PLT、ESR、CRP)水平在第14周高于VDZ治疗组,营养指标ALB水平在第30周低于VDZ治疗组,其差异具有统计学意义(P<0.05);其余实验室指标在各随访节点之间的差异无统计学意义(P>0.05)。IFX治疗组及VDZ治疗组的临床应答率在治疗第14周(81.8%vs 85.5%)、第30周(80.8%vs 92.5%)及第54周(91.3%vs 90.0%)无显著差异(P>0.05);临床缓解率在治疗第14周(41.8%vs 49.1%)、第30周(50.0%vs 67.5%)及第54周(65.2%vs 63.3%)无显著差异(P>0.05);内镜应答率在治疗第14周(54.3%vs 72.2%)、第30周(41.2%vs 73.3%)及第54周(60.0%vs 75.0%)无显著差异(P>0.05);内镜缓解率在治疗第14周(34.3%vs 55.6%)及第54周(53.3%vs 54.2%)无显著差异(P>0.05),IFX治疗组的内镜缓解率在治疗第30周(23.5%vs 73.3%)低于VDZ治疗组,其差异具有统计学意义(P=0.005)。IFX治疗组与VDZ治疗组的失应答率在治疗14周至30周期间(7.3%vs 1.8%)无显著差异(P>0.05),IFX治疗组的失应答率在治疗第30周至54周期间(16.4%vs 0)高于VDZ治疗组,其差异具有统计学意义(P=0.005);IFX治疗组及VDZ治疗组不良反应发生率(10.9%vs 5.5%)之间差异无统计学意义(P>0.05)。结论在中重度UC的治疗中,IFX治疗组与VDZ治疗组在第14周、54周的临床应答率及临床缓解率、内镜应答率、内镜缓解率之间未观察到显著差异,在第30周IFX治疗组的内镜缓解率低于VDZ治疗组;维持治疗过程中IFX治疗组的失应答率高于VDZ治疗组,提示IFX治疗组可能存在更高的远期耐药率;两药物治疗过程中的不良反应发生率之间无显著差异。
Objective To compare the efficacy and safety of Infliximab(IFX)and Vedolizumab(VDZ)in the treatment of moderate-to-severe ulcerative colitis(UC).Methods A total of 110 patients diagnosed with moderate-to-severe ulcerative colitis and treated with IFX/VDZ in the First Affiliated Hospital of Kunming Medical University from January 2020 to December 2023 were retrospectively collected.Including 55 in the IFX treatment group and 55 in the VDZ treatment group.Clinical symptoms,indicators related to disease activity,endoscopic manifestations and adverse reactions occurred during treatment were recorded before treatment(0 weeks)and 14,30,and 54 weeks of treatment,and whether there were differences in the efficacy and safety of the two drugs in the treatment of moderate to severe UC was analyzed.Results There were no significant differences in baseline indexes between the two groups(P>0.05).The levels of inflammatory indicators(WBC,PLT,ESR,CRP)in IFX treatment group were higher than those in VDZ treatment group at week 14,and the level of nutrition indicator ALB was lower than those in VDZ treatment group at week 30,with statistical significance(P<0.05).There was no significant difference in other laboratory indexes among follow-up time points(P>0.05).The clinical response rate of IFX treatment group and VDZ treatment group was not significantly different at week 14(81.8%vs 85.5%),week 30(80.8%vs 92.5%)and week 54(91.3%vs 90.0%)(P>0.05).There was no significant difference in clinical response rate at week 14(41.8%vs 49.1%),week 30(50.0%vs 67.5%)and week 54(65.2%vs 63.3%)(P>0.05).There was no significant difference in endoscopic response rate at week 14(54.3%vs 72.2%),week 30(41.2%vs 73.3%)and week 54(60.0%vs 75.0%)(P>0.05).There was no significant difference in the endoscopic remission rate at week 14(34.3%vs 55.6%)and week 54(53.3%vs 54.2%)(P>0.05).The endoscopic remission rate at week 30(23.5%vs 73.3%)in IFX treatment group was lower than that in VDZ treatment group,the difference was statistically significant(P=0.005).There was no significant difference between IFX group and VDZ group(7.3%vs 1.8%)during 14 to 30 weeks of treatment(P>0.05),and IFX group had higher non-response rate during 30 to 54 weeks of treatment(16.4%vs 0)than VDZ group.The difference was statistically significant(P=0.005).There was no significant difference in the incidence of adverse reactions between IFX treatment group and VDZ treatment group(10.9%vs 5.5%)(P>0.05).Conclusion During the treatment of moderate to severe UC,no significant difference was observed in the clinical response rate,clinical remission rate,endoscopic response rate and endoscopic remission rate between the IFX treatment group and the VDZ treatment group at week 14 and week 54,and the endoscopic remission rate in the IFX treatment group was lower than that in the VDZ treatment group at week 30.The non-response rateof IFX treatment group was higher than that of VDZ treatment group during maintenance treatment,suggesting that IFX treatment group may have a higher long-term drug resistance rate.There was no significant difference in the incidence of adverse reactions between the two drugs.
作者
张瀚予
罗娟
董明志
陈杞殷
张峰睿
郭蕊
童俊英
缪应雷
ZHANG Hanyu;LUO Juan;DONG Mingzhi;CHEN Qiyin;ZHANG Fengrui;GUO Rui;TONG Junying;MIAO Yinglei(Dept.of Gastroenterology,The 1st Affiliated Hospital of Kunming Medical University,Kunming Yunnan 650032;Yunnan Provincial Clinical Research Center for Digestive Diseases,Kunming Yunnan 650032;Dept.of Gastroenterology,The 2nd People’s Hospital of Baoshan,BaoshanYunnan 678000;Dept.of Gastroenterology,The People’s Hospital of Wuhua District,Kunming Yunnan 650032,China)
出处
《昆明医科大学学报》
CAS
2024年第10期36-44,共9页
Journal of Kunming Medical University
基金
国家自然科学基金资助项目(82170550)
云南省消化系统疾病临床医学研究中心-云南省疑难危重消化系统疾病研究及推广应用子课题(202002AA100205)
云南省基础研究基金资助项目(202301AS070027)
兴滇英才支持计划项目(2024-04-15)。
